CLX Medical, Inc. Updates Process of Validation Study for Zonda, Inc.'s Rapid Point of Care Test for Chlamydia

Published: May 21, 2008

MURRIETA, CA--(Marketwire - May 21, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the first stages of a pre-clinical trials validation study on Zonda Incorporated's rapid point of care test for chlamydia have been initiated and that the testing itself is expected to commence once the required chlamydia cells have been grown and laboratory staff has been properly trained in the study procedures.

Back to news